Virbac share briefly breaks through its 302 € support before rebounding
The veterinary laboratory from Carros is declining in trading in a pressured Paris market, as the SBF 120 loses more than one percentage point amid budgetary uncertainty in France. The decline brings the share below its main moving averages, in a monthly and quarterly momentum that remains negative.
An intraday break through the 302 € support quickly recovered, but pressure remains present
The Virbac share is down 2.09% at 305 € in trading, after briefly falling below its 302 € support during the morning session, with a low touched at 301.50 €. The share quickly moved back above this threshold, returning around 302 €, but the configuration remains tense. Over one month, the decline reaches 5.43%, and over three months it exceeds 8%.
The share is trading below its three moving averages: the MA20 at 310.70 € (gap of 1.83%), the MA50 at 324.93 € (gap of 6.13%) and the MA200 at 345.21 € (gap of 11.65%). The RSI at 45 remains in neutral territory, with no marked signal of selling exhaustion for the time being. The next resistance to watch is located at 332 €, well above the current price.
A solid first half and confirmed objectives, but governance was also strengthened in late September
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The fundamental backdrop remains constructive. When publishing H1 2026 results on July 20, 2026, Virbac had confirmed its annual objectives, positioning itself in the upper end of its growth range, with projected revenue of 1,574.5 million euros. The group had then posted organic growth of 7.4% in the first half, in a context of share decline that had led to a difficult session on September 18.
Furthermore, the composition of the board of directors changed effective September 17, 2026: a censor joined the board and the audit committee was strengthened with a new member, according to a press release dated September 28. These governance adjustments are part of a normalization period following the results. In a Paris market weighed down by tension on French sovereign debt, with the 10-year OAT approaching its highest level since July 2008 at 4.75% according to the Banque de France statement from September 30, the 302 € support remains the immediate threshold to confirm in order to stabilize the price.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
